RE: Risk of HBV Reactivation in HBsAg Negative and AntiHBc IgG Positive Patients Receiving Biologic Therapy

Turk J Gastroenterol. 2023 Mar;34(3):310. doi: 10.5152/tjg.2023.237002.

Authors

İlkay Ergenç¹, Haluk Tarık Kani¹, Murat Karabacak², Elif Cömert Özer³, Shahin Mehdiyev¹, Fuad Jafarov¹, Kerem Yiğit Abacar², Seda Kutluğ Ağaçkıran², Gizem Sevik², Rahmi Aslan¹, Fatma Alibaz Öner², Nevsun İnanç², Mehmet Pamir Atagündüz², Dilek Seçkin³, Yeşim Özen Alahdab¹, Tülin Ergun³, Haner Direskeneli², Özlen Atuğ¹

Affiliations

¹ Department of Internal Medicine, Division of Gastroenterology, Marmara University, School of Medicine, Istanbul, Turkey.
² Department of Internal Medicine, Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey.
³ Department of Dermatology, Marmara University, School of Medicine, Istanbul, Turkey.

No abstract available

MeSH terms

Biological Therapy
Hepatitis B Antibodies
Hepatitis B Surface Antigens*
Hepatitis B virus* / physiology
Humans
Immunoglobulin G

Substances

Hepatitis B Surface Antigens
Hepatitis B Antibodies
Immunoglobulin G